Laden…
methyl (E)-2-[(2S,3S,7aS,12bS)-3-ethyl-7a-hydroxy-8-methoxy-2,3,4,6,7,12b-hexahydro-1H-indolo[2,3-a]quinolizin-2-yl]-3-methoxyprop-2-enoate
7-Hydroxymitragynine (7-OH) is not just stronger kratom. It is a potent opioid-receptor-active kratom alkaloid now appearing in high-concentration consumer products, with reported dependence and opioid-like withdrawal. Synapedia frames 7-OH as a product-dependent, high-dependence-risk topic with uncertain labeling and serious depressant-combination risks.
Class
Opioide
Pharmacological context
Mechanism
7-Hydroxymitragynine is a potent opioid-receptor-active kratom...
Short read on known pharmacology
Interactions
No curated pairs visible
Curated visible combinations
Risk theme
Interpret risks carefully
Condensed from structured notes
High-dependence-risk 7-OH context
7-hydroxymitragynine is a potent opioid-receptor-active kratom alkaloid now appearing in high-concentration consumer products. Reported dependence, craving, and opioid-like withdrawal are central to the risk picture, especially when tablets, shots, gummies, drink mixes, extracts, or uncertain labels are involved.
If you are in trouble
For breathing problems, chest pain, seizure, fainting, confusion, severe dehydration, severe uncontrolled vomiting or diarrhea, or suicidal thoughts, seek urgent medical help. In the U.S., Poison Control is available at 1-800-222-1222.
A botanical product with multiple alkaloids, variable composition, and dependence potential. It is not automatically safe, but it is not the same risk category as isolated or enriched 7-OH products.
A potent opioid-receptor-active alkaloid context where product strength, label uncertainty, depressant combinations, dependence, and opioid-like withdrawal deserve front-page attention.
Receptor Targets
Mechanism of Action
Designations
IUPAC: (E)-2-[(2S,3S,7aS,12bS)-3-ethyl-7a-hydroxy-8-methoxy-2,3,4,6,7,12b-hexahydro-1H-pyrido[2,1-a]beta-carbolin-2-yl]-3-methoxy-acrylic acid methyl ester
Legal Status
Legal status not verified by official sources. Please check current legislation independently.
Information without guarantee. Not legal advice.
Synapedia Evidence
7-Hydroxymitragynine is a potent opioid-receptor-active kratom alkaloid. Several preclinical models suggest stronger opioid-system activity than mitragynine, while consumer-product risk depends heavily on concentration, conversion, labeling accuracy, and co-ingredients.
Known Effects
Individual effects may vary significantly. These are pharmacologically documented effects.
Total duration 4–6 hours
Onset
30–60 minutes
Peak
1–2 hours
Total duration
4–6 hours
After effects
2–4 hours
Avoid uncertain dosage claims and do not infer numbers when data is unclear.
Dose sensitivity varies greatly between individuals. Body weight, tolerance, route of administration, combinations, and pre-existing conditions significantly affect outcomes. These figures are not dosing recommendations — they describe reported ranges, not safe amounts.
Risks
Summary
Mögliche Nebenwirkungen und Abhängigkeit.
Safer Use
The risks listed may be incomplete. Especially for research chemicals and rare substances, available data is limited.
Interaction details from the knowledge layer are still being translated.
Interaction data is based on known mechanisms. Unknown or rare interactions are possible and may be life-threatening.
Based on substance class, receptors, mechanisms, and effect profile.
This information is for scientific and harm-reduction purposes only. It does not constitute medical advice.
Share a report, observation, or question about this substance. Entries are reviewed before publication and marked as unverified community signals.
These entries are submitted by users and are not verified. They may contain subjective experiences, observations, source leads, or corrections. They do not replace scientific data and are not consumption advice.
The signal hub collects approved risk signals, experience reports and source leads by relevance.